Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice

Journal of Psychiatric Research

Volumn 47, Issue 6, 2013, Pages 802-808

  Engel, Daiane ^a   Zomkowski, Andréa D E ^a   Lieberknecht, Vicente ^a   Rodrigues, Ana Lúcia ^a   Gabilan, Nelson H ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Antidepressants; Apoptotic proteins; Duloxetine; Mirtazapine; Neuroprotection; Neurotrophins

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; FIBROBLAST GROWTH FACTOR 2; MIRTAZAPINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN PROTECTION; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FEMALE; FORCED SWIMMING TEST; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION;

EID: 84875889629     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.02.013     Document Type: Article

References (47)

1. Abelaira H.M., Réus G.Z., Ribeiro K.F., Zappellini G., Ferreira G.K., Gomes L.M., et al. Effects of acute and chronic treatment elicited by lamotrigine on behavior, energy metabolism, neurotrophins and signaling cascades in rats. Neurochemistry International 2011, 59:1163-1174.
2. Agostinho F.R., Réus G.Z., Stringari R.B., Ribeiro K.F., Pfaffenseller B., Stertz L., et al. Olanzapine plus fluoxetine treatment increases NT-3 protein levels in the rat prefrontal cortex. Neuroscience Letters 2011, 22(497):99-103.
3. Alfonso J., Frick L.R., Silberman D.M., Palumbo M.L., Genaro A.M., Frasch A.C. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biological Psychiatry 2006, 59:244-251.
4. Bachis A., Mallei A., Cruz M.I., Wellstein A., Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008, 55:1114-1120.
5. Banasr M., Dwyer J.M., Duman R.S. Cell atrophy and loss in depression: reversal by antidepressant treatment. Current Opinion in Cell Biology 2011, 23:730-737.
6. Bremner J.D. Structural changes in the brain in depression and relationship to symptom recurrence. CNS Spectrums 2002, 7:129-130. 135-9.
7. Calabrese F., Molteni R., Maj P.F., Cattaneo A., Gennarelli M., Racagni G., et al. Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007, 32:2351-2359.
8. Calabrese F., Molteni R., Cattaneo A., Macchi F., Racagni G., Gennarelli M., et al. Long-term duloxetine treatment normalizes altered brainderived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Molecular Pharmacology 2010, 77:846-853.
9. Calcagno E., Canetta A., Guzzetti S., Cervo L., Invernizzi R.W. Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. Journal of Neurochemistry 2007, 103:1111-1120.
10. Chao C.C., Ma Y.L., Lee E.H.Y. Brain-derived neurotrophic factor enhances bcl-xl expression through protein kinase casein kinase2-activated and nuclear factor kappa B-mediated pathway in rat hippocampus. Brain Pathology 2010, 21:150-162.
11. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. Journal of Biological Chemistry 1999, 274:6039-6042.
12. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309:1732-1735.
13. Cowen D.S. Serotonin and neuronal growth factors - a convergence of signaling pathways. Journal of Neurochemistry 2007, 101:1161-1171.
14. Culmsee C., Mattson M.P. p53 in neuronal apoptosis. Biochemical and Biophisical Research Communications 2005, 331:761-777.
15. Evans S.J., Choudary P.V., Neal C.R., Li J.Z., Vawter M.P., Tomita H., et al. Dysregulation of the fibroblast growth factor system in major depression. Proceedings of the National Academy of Sciences USA 2004, 101:15506-15511.
16. Gottlieb T.M., Leal J.F., Seger R., Taya Y., Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002, 21:1299-1303.
17. Guidotti G., Calabrese F., Auletta F., Olivier J., Racagni G., Homberg J., et al. Developmental influence of the serotonin transporter on the expression of Npas4 and GABAergic markers: modulation by antidepressant treatment. Neuropsychopharmacology 2012, 37:746-758.
18. Hart T., Brenner L., Clark A.N., Bogner J.A., Novack T.A., Chervoneva I., et al. Major and minor depression after traumatic brain injury. Archives of Physical Medicine and Rehabilitation 2011, 92:1211-1219.
19. Huang Y.Y., Peng C.H., Yang Y.P., Wu C.C., Hsu W.M., Wang H.J., et al. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stems cells. Journal of Pharmacological Sciences 2007, 104:61-72.
20. Jacobs W.B., Kaplan D.R., Miller F.D. The p53 family in nervous system development and diseases. Journal of Neurochemistry 2006, 97:1571-1584.
21. Karpa K.D., Cavanaugh J.E., Lakoski J.M. Duloxetine pharmacology: prole of a dual monoamine modulator. CNS Drug Reviews 2002, 8:361-376.
22. Kosten T.A., Galloway M.P., Duman R.S., Russell D.S., D'Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
23. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
24. Lindsten T., Zong W.-X., Thompson C.B. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005, 11:10-15.
25. Mallei A., Shi B., Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Molecular Pharmacology 2002, 61:1017-1024.
26. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., Riva M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biological Psychiatry 2004, 55:1095-1102.
27. McKernan D.P., Timothy D.G., John C.F. ''Killing the Blues'': a role for cellular suicide (apoptosis) in depression and the antidepressant response?. Progress in Neurobiology 2009, 88:246-263.
28. Molteni R., Calabrese F., Cattaneo A., Mancini M., Gennarelli M., Racagni G., et al. Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 2009, 34:1523-1532.
29. Muir J.K., Raghupathi R., Emery D.L., Bareyre F.M., McIntosh T.K. Postinjury magnesium treatment attenuates traumatic brain injury- induced cortical induction of p53 mRNA in rats. Experimental Neurology 1999, 159:584-593.
30. Nowakowska E., Chodera A., Kus K. Behavioral and memory improving effects of mirtazapine in rats. Polish Journal of Pharmacology 1999, 51:463-469.
31. Overstreet D.H., Fredericks K., Knapp D., Breese G., McMichael J. Nerve growth factor (NGF) has novel antidepressant-like properties in rats. Pharmacology, Biochemistry and Behavior 2010, 94:553-560.
32. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 2007, 62:1217-1227.
33. Peña S., Baccichet E., Urbani M., Carreira I., Lima L. Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. International Immunopharmacology 2005, 5:1069-1076.
34. Peng C., Chiou S., Chen S., Chou Y., Ku H., Cheng C., et al. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. European Neuropsychopharmacology 2008, 18:128-140.
35. Pittenger C., Duman R. Stress, depression, and: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
36. Putcha G.V., Harris C.A., Moulder K.L., Easton R.M., Thompson C.B., Johnson E.M. Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. Journal of Cell Biology 2002, 57:441-453.
37. Prickaerts J., De Vry J., Boere J., Kenis G., Quinton M.S., Engel S., et al. Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex. Journal of Molecular Neuroscience 2012, 48:167-175.
38. Réus G.Z., Abelaira H.M., Agostinho F.R., Ribeiro K.F., Vitto M.F., Luciano T.F., et al. The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain. Journal of Psychiatric Research 2012, 46:1029-1035.
39. Robinson R.G., Spalletta G. Poststroke depression: a review. Canadian Journal of Psychiatry 2010, 55:341-349.
40. Rogóz Z., Skuza G., Legutko B. Repeated treatment with mirtazapine induces brain-derivated neurotrophic factor gene expression in rats. Journal of Physiology and Pharmacology 2005, 56:661-671.
41. Schütte A., Yan Q., Mestres P., Giehl K.M. The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms. Neuroscience Letters 2000, 290:185-188.
42. Sheline Y.I. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biological Psychiatry 2000, 48:791-800.
43. Shirayama Y., Chen A.C.-H., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Journal of Neuroscience 2002, 22:3251-3261.
44. Wang Y., Xiao Z., Liu X., Berk M. Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. Human Psychopharmacology 2011, 26:95-101.
45. Xu H., Richardson J.S., Li X.M. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003, 28:53-62.
46. Zhang Y., Gu F., Chen J., Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Research 2010, 1366:141-148.
47. Zomkowski A.D., Engel D., Cunha M.P., Gabilan N.H., Rodrigues A.L. The role of the NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test. Pharmacology, Biochemestry and Behavavior 2012, 103:408-417.